STOCK TITAN

QuidelOrtho Corporation (QDEL) 10-K Filings

QDEL NASDAQ

Here are the 10-K annual reports from QuidelOrtho Corporation (QDEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow QDEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QDEL filings page.

Form 10-K
Rhea-AI Summary

QuidelOrtho Corporation provides a detailed annual overview of its global diagnostics business, spanning Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine across more than 140 countries. The company highlights U.S. manufacturing and service scale, including about 6,500 employees and roughly 1,200 service staff.

QuidelOrtho is winding down its U.S. donor screening portfolio, including the VIP platform and microplate assays, with completion expected by the first half of 2026, and has decided to discontinue development of the SAVANNA molecular platform. Respiratory products represented about 15% of total 2025 revenues, reflecting strong seasonality.

The company continues to invest in R&D, with expenses of $186.2 million, $218.7 million and $245.0 million for fiscal years 2025, 2024 and 2023, respectively. It recorded a $65 million charge payable to Grifols over three years tied to mutually agreed terms in principle for an early termination of their long‑running Joint Business arrangement. As of February 11, 2026, 68,081,767 common shares were outstanding, and the aggregate market value of common stock held by non‑affiliates was $1,940,523,408 as of the last business day of the most recent second fiscal quarter.